Introduction
============

Acetylcholine (ACh), a neurotransmitter released from nerve terminals of postganglionic parasympathetic neurons, promote the contraction of airway smooth muscles as well as mucus secretion via muscarinic type 3 (M~3~) receptor in the airways ([@B56]; [@B39]). It has been also revealed that non-neuronal cells including airway epithelial cells can synthesize and release ACh, which may induce biological functions in an autocrine or paracrine manner ([@B53]; [@B36]). ACh is significantly involved in the pathogenesis of COPD because the activity of the cholinergic system is increased in this disease augmenting the airflow limitation and hypersecretion ([@B24]). In addition to these roles in the pathogenesis of COPD, accumulating evidence has revealed that ACh can regulate inflammatory responses. In this review, we summarize recent literature on the roles of cholinergic pathways in inflammation, especially focusing on: (1) pro-inflammatory effects of ACh through mAChRs; (2) possible benefits of the combinations of long-acting β2 adrenergic agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) in terms of regulating inflammation; (3) anti-inflammatory effects of ACh via the α7 nicotinic acetylcholine receptor (α7nAChR); (4) recent advances in clarifying neuroimmune interactions that regulating innate lymphoid cells (ILCs), which could lead to potential pharmacotherapeutic targets for COPD.

Pro-Inflammatory Actions of ACh Through Muscarinic ACh Receptors in Airways
===========================================================================

In addition to the role of ACh in neurotransmission, the activation of muscles and mucus secretion, accumulating evidence from animal studies using muscarinic antagonists or subtype-specific deficient mice has suggested that ACh can augment airway inflammation through muscarinic ACh receptors. Tiotropium, one of the LAMAs with higher selectivity for M~3~ receptors, inhibited pulmonary neutrophilic inflammation and the release of leukotriene B4 (LTB4), interleukin-6 (IL-6), keratinocyte-derived chemokine(KC; IL-8 in humans), monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha and -2 (MIP-1α and MIP-2), and tumor necrosis factor alpha (TNF-α) in a mouse COPD model induced by cigarette smoke ([@B77]). Tiotropium also attenuated neutrophil infiltration and the elevation of IL-6 and TNF-α in cigarette smoke and virus-exposed mice ([@B6]). Glycopyrronium, another M~3~-selective LAMA, attenuated the accumulation of neutrophils and macrophages and the elevation of inflammatory cytokines and chemokines induced by both acute and subchronic cigarette smoke exposure ([@B62]; [@B26]). Aclidinium bromide, another M~3~-selective LAMA, also attenuated neutrophilic infiltration in the alveolar septa in a cigarette smoke--exposed guinea pig model of COPD ([@B16]). Although these LAMAs are kinetically selective for M~3~ receptors due to their dissociation time from M~3~ being longer than that from M~2~ or M~1~, the binding affinity of these agents for M~1~, M~2~, and M~3~ are similar and have limited selectivity ([@B11]), meaning that it is still unclear which muscarinic receptor subtype was critical for the pro-inflammatory effects in a cigarette smoke-exposed animal model of COPD. To answer this question, gene-targeting in mice for each subtype of muscarinic receptor was employed. M~3~ receptor-deficient mice showed a decrease in both neutrophil accumulation in the lungs and the release of KC, a neutrophil chemotactic factor, in an acute cigarette smoke-exposed mouse model ([@B31]). In contrast to M~3~ receptor-deficient mice, M~2~ receptor-deficient mice showed an increase in both neutrophil infiltration in the airspaces and the release of KC after exposure to cigarette smoke ([@B31]). Because the M~2~ receptor is located on the pre-junctions of pre- and post-ganglionic pulmonary parasympathetic nerves and acts as a feedback inhibitory receptor limiting acetylcholine release ([@B19]; [@B18]; [@B43]), the levels of ACh are increased in the airway of M~2~ receptor-deficient mice causing an enhancement of neutrophilic inflammation via the M~3~ receptor. Mice deficient in the M~1~ receptor, which is expressed on parasympathetic ganglia and mediate neurotransmission, also shows a remarkable enhancement of neutrophil inflammation after cigarette smoke-exposure ([@B31]). This seems to be paradoxical because a M~1~ receptor deficiency would cause a reduction of acetylcholine in the airway, resulting the reduction of inflammation. Because M~1~ receptors are also expressed on airway epithelial cells and regulate electrolyte and water secretion ([@B28]), a hypothesis explaining this paradox is that the clearance of smoke particles is impaired in M~1~ deficient mice. *In vitro* cell culture experiments also supported the pro-inflammatory actions of ACh thorough muscarinic receptors on airway parenchymal cells and inflammatory cells (Table [1](#T1){ref-type="table"}). Because M~3~ receptors are expressed in various types of cells including parenchymal cells and hematopoietic cells in airways (Table [1](#T1){ref-type="table"}), the question has arisen whether the pro-inflammatory effects of ACh via M~3~ receptors are mediated mainly by parenchymal cells or inflammatory cells. To answer this question, bone marrow chimeric mice were established. This investigation revealed that the accumulation of neutrophils in the airways was inhibited in M~3~ receptor-deficient mice with wild-type bone marrow, whereas wild-type mice with M~3~ receptor-deficient bone marrow showed a comparable increase in neutrophil accumulation, suggesting that M3 receptors of the airway parenchymal cells are primarily involved in the pro-inflammatory effects of ACh during cigarette smoke-induced inflammation ([@B33]).

###### 

Pro-inflammatory effects of ACh on parenchymal and leukocytes via muscarinic receptors.

  Type of cells           Type of receptors              Actions                                                                                                            Reference
  ----------------------- ------------------------------ ------------------------------------------------------------------------------------------------------------------ -----------------------
  **Parenchymal cells**                                                                                                                                                     
  Epithelial cells        M~1,~ M~2~, M~3~               Inducing the release of IL-8                                                                                       [@B52]
                                                         Stimulating the release of LTB~4~                                                                                  [@B51]
                                                         Augmenting IL-17A-induced release of IL-8                                                                          [@B2]
  Fibroblasts             M~1,~ M~2~, M~3~               Augmenting IL-1β-induced release of IL-6 and IL-8                                                                  [@B14]
  Smooth muscle cells     M~2~, M~3~                     Stimulating the release of IL-6 and IL-8                                                                           [@B23]
  **Leukocytes**                                                                                                                                                            
  Macrophages             M~1,~ M~2~, M~3~, M~4,~ M~5~   Stimulating the release of LTB~4~                                                                                  [@B60]; [@B8]; [@B35]
  Neutrophils             M~2~, M~3~, M~4,~ M~5~         Stimulating the release of IL-8                                                                                    [@B42]
                                                         Augmenting inflammatory mediator and matrix metalloproteinase release induced by LPS and cigarette smoke extract   [@B42]
  Mast cell               M~1~, M~3~, M~4,~ M~5~         Inhibiting the release of histamine                                                                                [@B55]
  Lymphocytes             M~1~, M~2~, M~3~, M~4,~ M~5~   Augmenting the production of antibodies and cytokines                                                              [@B20]
                                                                                                                                                                            

Although there is accumulating evidence for a significant role of ACh as a pro-inflammatory factor in COPD as well as clinical evidence showing that LAMAs decrease exacerbations of COPD, stronger evidence for its pro-inflammatory role in COPD patients is still limited. Treatment with tiotropium in COPD patients decreased the annual rate of exacerbations. However, the amount of IL-6 and myeloperoxidase in sputum did not decrease. Moreover, the concentration of IL-8 and MMP-9 increased in the sputum of the group treated with tiotropium ([@B50]; [@B48]). Tiotropium treatment also did not significantly decrease IL-6 or C-reactive protein in the serum ([@B50]). This is possibly due to the fact that tiotropium decreased the amount of mucus secretion, causing a higher concentration of the mediators in sputum. It has been reported that targeted lung denervation of parasympathetic nerves in patients with COPD induces a reduction of neutrophil accumulation and inflammatory mediators including IL-8 ([@B32]). This is the first direct evidence showing that ACh acts a pro-inflammatory factor in actual COPD patients. Further investigations including histological evaluations by bronchial biopsy will be needed to elucidate whether antimuscarinic drugs actually effect inflammation in COPD patients.

Possible Benefits of the Combinations of LABAs and LAMAs in Terms of Regulating Inflammation During COPD
========================================================================================================

Several clinical studies have reported that the combination of LABA and LAMA reduces exacerbations more than the use of LABA or LAMA alone ([@B75]; [@B9]). LABA/LAMA combinations decrease hyperinflation ([@B4]; [@B70]) and symptom severity ([@B38]; [@B7]; [@B47]), and improve sputum clearance ([@B50]; [@B41]; [@B67]), all of which may contribute to decreasing exacerbations. Although the effects of the LABA/LAMA combination therapy against inflammation have not been demonstrated in patients with COPD, nor has LAMA or LABA alone, several mechanisms are possibly involved in the synergistic actions of the LABA/LAMA combination against inflammation (Figure [1](#F1){ref-type="fig"}). One of the possible mechanisms is that LABA and LAMA synergistically inhibit the release of non-neurogenic acetylcholine from bronchial epithelial cells. A recent report showed that, although single administration of glycopyrronium or indacaterol did not modify the release of acetylcholine from primary human bronchial epithelial cells, the combination of glycopyrronium and indacaterol significantly reduced the release of acetylcholine ([@B12]). This effect may originate through the modulation of organic cation transporter 1, a transporter for the release of acetylcholine from airway epithelial cells ([@B59]). This mechanism may contribute to the anti-inflammatory effects by reducing the levels of acetylcholines, which have pro-inflammatory effects via M~3~ receptors. Another possible mechanism is that LABA and LAMA synergistically inhibit the release of pro-inflammatory factors from parenchymal cells or inflammatory cells. Tiotropium or olodaterol attenuates the production of reactive oxygen species (ROS), NOX-4 protein expression, and IL-8 release from 16HBE cells induced by cigarette smoke extract (CSE), and the combination of LABA and LAMA provides stronger effects compared to LAMA or LABA alone ([@B1]). Tiotropium or olodaterol reduces neutrophil adhesion and the expression of macrophage-1 antigen (MAC-1) adhesion protein on neutrophils stimulated by sputum supernatants from patients with COPD. The combination of these agents augments these effects. Olodaterol attenuates neutrophil accumulation and pro-inflammatory mediators in the airway of cigarette smoke or LPS-induced murine and guinea pig lung inflammation models, and also attenuates the release of TNF-α from blood leukocytes and reduces CD11b adhesion molecule expression on granulocytes *in vitro* ([@B76]). Recent studies showed that β2-receptor agonists attenuated the release of TNF-α and MCP-1 induced by LPS from a mouse macrophage cell line by mediating the cAMP-dependent inhibition of ERK and p38MAPK pathways ([@B29], [@B30]). Because a M~3~ mAChR antagonist attenuated the production of TNF-α induced by LPS from alveolar macrophages via mediating the NF-κB signaling pathway, combinations of these drugs may possibly inhibit the release of pro-inflammatory factors synergistically also in terms of intracellular signaling ([@B78]). To confirm these suggested mechanisms in the synergistic effects by the LABA/LAMA combination in COPD patients, further clinical investigations will be needed.

![Possible mechanisms of synergistic actions of the LABA/LAMA combination against inflammation. **(A)** Synergistic inhibitory effect of LABA/LAMA against ACh release from airway epithelial cells. Signaling via β~2~AR inhibits the function of OCT1, a transporter for the release of acetylcholine from airway epithelial cells, whereas signaling via M~3~ possibly upregulates the function of OCT1. Therefore, the LABA/LAMA combination synergistically inhibits the release of ACh. **(B)** Synergistic inhibitory effect of LABA/LAMA against the production of inflammatory mediators. Signaling via β~2~AR activates AC-cAMP-PKA signaling pathway. PKA inhibits ERK and p38MAPK pathways. In contrast, signaling via M~3~ activates PKC, which results in the activation of NF-κB. The combination of LABA and LAMA therefore possibly inhibits the production of pro-inflammatory mediators synergistically via inhibiting both MAPK and NF-κB pathways. ACh, acetylcholine; AC, adenylate cyclase; β~2~AR, beta-2 adrenergic receptor; cAMP, cyclic adenosine monophosphate; CHT1, high-affinity choline transporter 1; ERK, extracellular signal-regulated kinase; LABA, long-acting β~2~ agonist; LAMA, long-acting muscarinic antagonist; MAPK, mitogen-activated protein kinase; M~3~, acetylcholine muscarinic M3 receptor; NF-κB, nuclear factor-kappa B; OCT1, organic cationic transporter 1; PKA, protein kinase A; PKC, protein kinase C.](fphar-09-01426-g001){#F1}

Anti-Inflammatory Effects of ACh Via the α7 Nicotinic Acetylcholine Receptor (α7nAchR)
======================================================================================

In contrast to the pro-inflammatory effects by ACh through muscarinic ACh receptors, it has been elucidated that there is a cholinergic anti-inflammatory pathway which includes parasympathetic nerves that regulate the inflammatory responses to maintain the body during tissue injury and infection. An investigation with gene-deficient animal models revealed that α7nAChR on splenic macrophages was critical for attenuating the inflammatory response by ACh in an LPS-induced animal septic model ([@B73]). Further investigations revealed that the efferent vagus nerve stimulates sympathetic neurons of the splenic nerve, and then NE produced by the splenic nerve stimulates splenic T cells expressing β2-adrenergic receptors causing the production of ACh, which can bind to α7nAChR on splenic macrophages ([@B57]; [@B58]; [@B69]).

In airways, ACh is derived from parasympathetic postganglionic neurons or non-neuronal cells including epithelial cells and can possibly bind to α7nAChR on macrophages and other inflammatory cells attenuating inflammation. An experiment using a mouse model of acid-induced acute lung injury or sepsis-induced acute lung injury showed that α7nAChR is expressed on alveolar macrophages and neutrophils, and activation of α7nAChR by nicotine or PNU-282987, a specific agonist, reduced the inflammatory responses and attenuated the severity of lung injury, whereas the lung injury became worse in α7nAChR-deficient mice ([@B63], [@B64]). In a rodent lung injury model of ventilator-induced lung injury, intestinal ischemia-reperfusion, severe acute pancreatitis and cardiopulmonary bypass-induced lung ischemia-reperfusion, the activation of α7nAChR provided protective effects against lung injury ([@B17]; [@B25]; [@B37]; [@B22]). The exact mechanism by which the activation of α7nAChR induced anti-inflammatory effects is still not clear. The activation of a7 nAChR by a specific agonist in monocytes epigenetically increases histone deacetylation, which decreases in the NF-κB p65 activity of transcription factors including NF-κB, and the transcription of pro-inflammatory cytokine genes ([@B79]). In *E. coli* and LPS-induced lung injury mouse models, vagotomy augmented the lung recruitment of α7nAChR^+^ CD11b^+^ monocytes and neutrophils. The activation of α7nAChR by an agonist suppressed the recruitment of α7nAChR^+^ CD11b^+^ monocytes and neutrophils. The phosphorylation of serine 473 of AKT1 via α7nAChR signaling is involved in the attenuation of the lung recruitment of these inflammatory cells ([@B81]). It has been also reported that activation of α7nAChR attenuates the polarization of alveolar macrophages to the pro-inflammatory M1 phenotype, whereas M2 macrophages were increased in an LPS-induced lung injury model ([@B49]; [@B74]).

In contrast to acute lung injury models showing the protective effect of α7nAChR against inflammation, there is a report suggesting that signaling via α7nAChR may worsen fibrosis in the lungs. In a mouse bleomycin-induced lung fibrosis model, the severity of lung fibrosis, including histological scoring and the expression of fibrogenic genes, was attenuated in α7nAChR deficient mice. The activation of α7nAChR by GTS-21 (an α7nAChR agonist) increased the TGF-β-induced phosphorylation of Smad2/3 and transcription of fibrogenic genes in lung fibroblasts ([@B66]). Another report showed that nicotine stimulated collagen type I mRNA and protein expression in primary lung fibroblasts. This effect of nicotine was not observed in α7nAChR-deficient primary lung fibroblasts. *In vivo* administration of nicotine increased collagen type I expression in the wild type, but not in α7nAChR-deficient mice ([@B68]). These reports suggest that α7nAChR signaling in lung fibroblasts is involved in the pathogenesis of fibrotic lung diseases and airway remodeling.

It has been reported that airway epithelial cells also express α7nAChR ([@B63]; [@B21]). Reporter gene analyses for α7nAChR expression in genetically modified mice revealed that α7nAChRs are expressed in club cells and alveolar type II cells as well as alveolar macrophages ([@B21]). α7nAChRs are likely involved in the regulation of proliferation, ion transport and responses to inflammatory stimuli ([@B46]; [@B40]; [@B21]). Moreover, α7nAChRs are expressed in non-small cell lung cancer cells and participate in tumor growth and epidermal-mesenchymal transition ([@B13]; [@B61]; [@B5]; [@B80]; [@B45]). Therefore, these tumor-promoting actions as well as pro-fibrotic actions via α7nAChRs could be serious barriers to employing α7nAChR agonists to attenuate inflammation in chronic inflammatory diseases such as COPD and asthma, which require continuous drug administration.

Recent Advances in Clarifying the Neuroimmune Interactions Regulating Innate Lymphoid Cells
===========================================================================================

It has been revealed that ILCs, which originate from common lymphoid cells but do not have antigen receptors, exist in various tissues of mammals including human, and can produce various cytokines in response to various stimuli including alarmins. ILCs are classified into type 1, type 2, and type 3 ILCs according to their functions and the cytokines produced ([@B71]). Recently, neurotransmitters including acetylcholine have been shown to likely participate in the regulation of proliferation and activation of ILCs (Figure [2](#F2){ref-type="fig"}). Type 2 innate lymphoid cells (ILC2s) produce significant amounts of Th2 cytokines and participate in airway allergic inflammation. A recent report described that α7nAChRs are expressed on ILC2s. The activation of α7nAChRs on ILC2s suppresses IL-5 and IL-13 production in ILC2s and ameliorates ILC2-induced airway hyperreactivity. α7nAChR agonist attenuates the expression of GATA3 and NF-κB in ILC2s as well as the proliferation of ILC2s. The activation of α7nAChR by an agonist also prevents human ILC2 mediated airway hyperreactivity as well as type 2 cytokine production and eosinophilic inflammation. These observations may suggest a protective role of α7nAChR signaling in ILC2s against ILC2-mediated allergic inflammation and the possibility that α7nAChR could be a potential therapeutic target for the treatment of ILC2-mediated asthma.

![Neuroimmune interaction regulating innate lymphoid cells. **(A)** Glucocorticoids derived from hypothalamic-pituitary-adrenal axis stimulated by inflammatory mediators during systemic inflammation bind to GRs in ILC1s, which inhibits the release of IFN-γ. **(B)** The activation of ILC2s by epithelial alarmin cytokines is inhibited by ACh derived from parasympathetic neurons and possibly non-neuronal cells via α7nAChR, or NA derived from sympathetic neurons via β~2~AR. In contrast, neuromedin U derived from DRG sensory neurons or CGRP derived from PNECs augments the activation of ILC2s via NMUR1 or CRLR, respectively. **(C)** RET ligand derived from glial cells or acetylcholine derived from parasympathetic neurons arguments the proliferation and activation ILC3s via RET or muscarinic receptors, respectively. α7nAChR, α7 nicotinic acetylcholine receptor; ACh, acetylcholine; APC, antigen-presenting cell; β~2~AR, beta-2 adrenergic receptor; CGRP, calcitonin gene-related peptide; CRLR, calcitonin receptor-like receptor; DRG, dorsal root ganglia; GCs, glucocorticoids; IFN-γ, interferon-gamma; ILCs, innate lymphoid cells; MR, acetylcholine muscarinic receptor; NA, norepinephrine; NMU, neuromedin U; NMUR1, neuromedin-U receptor 1; PNEC, pulmonary neuroendocrine cell; TNF-α, tumor necrosis factor-alpha.](fphar-09-01426-g002){#F2}

Other recent studies have shown that the neuropeptide neuromedin U (NMU) released from neural cells activates ILC2s and amplifies ILC2-driven allergic inflammation ([@B10]; [@B34]; [@B72]). In an airway allergic mouse model induced by intranasal administration of IL-25 and IL-33, single-cell RNA sequencing analyses were performed to profile mouse lung-resident ILCs and revealed that NMUR1, a receptor for NMU, was specifically expressed on ILC2s ([@B72]). Immunofluorescence microscopic analysis suggested that ILC2s were likely located close to nerve fibers. Sensory neurons in the dorsal root ganglia, but not parasympathetic neurons in the nodose/jugular ganglion, expressed NMU. IL-13 induced the upregulation of NMU in cultured dorsal root ganglia neurons. NMU can activate ILC2s and induce type 2 cytokine productions *in vitro*. Intranasal co-administration of NMU with IL-25 strongly amplified airway allergic inflammation. Moreover, NMUR1-deficient mice showed an attenuation of both the ILC2 frequency and effector function during airway inflammation from house dust mites. These findings indicated that NMU derived from sensory neurons innervated into airways can activate ILC2s, and this newly identified neuroimmune interaction is involved in the modulation of airway allergic inflammation ([@B72]).

Another study using RNA sequencing analyses of ILC2s revealed that mouse and human ILC2s express β~2~-adrenergic receptor (β~2~AR) ([@B44]). β~2~AR-deficient mice showed amplified ILC2 activation and airway allergic inflammation induced by intranasal stimulation with IL-33 or *Alternaria* extract, whereas the administration of β~2~ agonist attenuated the ILC2-responses and allergic inflammation. RNA-sequence analyses further showed that β~2~AR signaling pathway inhibits the cell proliferation and effector function of ILC2s. This study suggests that sympathetic adrenergic neurons that innervate the airways negatively regulate ILC2s via β~2~AR.

Pulmonary neuroendocrine cells (PNECs) are a unique but poorly understood cell population in the lungs. Although it has been reported that PNECs are increased in pulmonary diseases, including small-cell lung cancer, the precise role of PNECs in pulmonary diseases remains unknown. A recent report showed that PNECs have a significant role in the mucosal type 2 response in models of allergic asthma ([@B65]). PNECs act through calcitonin gene-related peptide (CGRP) to stimulate ILC2s and induce downstream immune responses, and also act through GABA to induce goblet-cell hyperplasia. These new findings demonstrated a novel neuroimmune system in the airway that augments the type 2 allergic response. It is still unknown how PNECs are activated following allergen challenge. PNECs are innervated by sensory afferents mostly from nodose ganglion neurons and vagal efferents, and this innervation of PNEC is required for the increased production of GABA ([@B3]), suggesting that stimulating efferent neurons that innervate PNECs may be involved in the activation of PNECs.

Compared with ILC2s, neuroimmune interactions that regulate the other ILCs, ILC3 and ILC1, in airways remain unclear, although it has been reported that their possible interactions may regulate other ILCs during systemic inflammation or inflammation of other organs. In gut, ILC3s express RET, a neuroregulatory receptor, and are localized close to glial cells expressing RET-ligands. Glial cells sense microenvironmental changes and release RET-ligands, causing ILC3 activation and the release of IL-22 ([@B27]). In a mouse *E. coli* peritonitis model, acetylcholine, probably via muscarinic receptors, upregulates ILC3 numbers, causing peritoneal macrophage production of a protective mediator, protectin conjugates in tissue regeneration 1 (PCTR1), and accelerate the resolution of inflammation induced by bacterial infection ([@B15]). In a study using an LPS-induced septic model, group 1 ILCs expressed glucocorticoid receptor and stimulation with glucocorticoids prevented IFN-γ production by ILC1s, which cause the development of IL-10-dependent tolerance to endotoxin ([@B54]).

These on-going investigations of neuroimmune crosstalk, including the cholinergic pathways in airways, may lead to new potential therapeutic targets not only for acute inflammation but also for chronic inflammatory respiratory diseases including COPD. However, we should also note that neurotransmitters participating in neuroimmune interactions also have other fundamental functions including neurotransmission, which means blocking these neurotransmitters could possibly cause critical adverse effects. Accordingly, we also have to take into account the delivery system for candidate drugs that regulate neuroimmune interactions.

Conclusion
==========

Accumulating evidence from *in vitro* and *in vivo* animal model investigations suggests that acetylcholine derived from parasympathetic neurons and non-neuronal cells can modulate airway inflammation. The pro-inflammatory actions of acetylcholine, mainly via M~3~ receptors, and possible synergistic anti-inflammatory effects of β~2~AR signaling may provide evidence for the benefit of treatment with LAMA or the combination of LABA/LAMA, although it remains unclear whether these treatments really have anti-inflammatory effects in COPD patients. Therefore, further clinical investigation will be needed to clarify the anti-inflammatory effects. Anti-inflammatory effects by acetylcholine via α7nAChR, which may modulate lung inflammation, have been revealed especially in systemic inflammation. However, we should be careful about other biological effects of α7nAChR signaling, including pro-fibrotic actions and tumor-promoting actions in terms of therapeutic utilization for chronic respiratory diseases including COPD. Recent on-going studies has revealed critical interactions between ILCs and neurotransmitters including acetylcholine. These newly found neuroimmune interactions may reveal therapeutic targets for airway inflammatory diseases. Further investigations will reveal novel effects of neurotransmitters including acetylcholine on immune systems and inflammation and may provide new therapeutic clues for clarifying airway inflammatory diseases such as COPD.
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